Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601
2015 ASTRO Annual Meeting
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).
James B. Yu, MD
James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).
Stephen G. Chun, MD
Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).
Roy Decker, MD, PhD
Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).
Jay Harris, MD
Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.
Anthony Zietman, MD
Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).